Incidence and resistance rates of Pseudomonas aeruginosa bloodstream infections in Switzerland: a nationwide surveillance study (2010–2022)
Infection · 2025-08 · 53 (4) · 1373-1381
DOI: 10.1007/s15010-024-02452-1 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Infection, online erschienen am 30.01.2025. Verfasst von Luzia Renggli und 5 weiteren Autor:innen. Beteiligte Einrichtung: Swiss Centre for Antibiotic Resistance (ANRESIS), Institute for Infectious Diseases, University of Bern, Bern, Switzerland. Hauptthemen laut MEDLINE: Pseudomonas aeruginosa, Pseudomonas Infections, Bacteremia, Drug Resistance, Bacterial. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Bern.
Abstract (Originalsprache)
Purpose
Bloodstream infections (BSIs) cause significant morbidity and mortality worldwide. Pseudomonas aeruginosa is an important microorganism in BSIs. The aim of this study was to analyze recent trends in the incidence and resistance rates of P. aeruginosa BSIs in Switzerland and its different linguistic regions.
Methods
This retrospective, nationwide observational study analyzed the incidence (using Poisson regression models) and antimicrobial resistance (using logistic regression models) of P. aeruginosa BSIs in Switzerland from 2010 to 2022.
Results
The annual incidence of P. aeruginosa BSIs in Switzerland increased from 5.5 BSIs per 100,000 inhabitants in 2010 to 7.6 BSIs per 100,000 inhabitants in 2022 ( p < 0.001). The incidence was higher in the French-speaking region than in the German-speaking region. The resistance rates increased significantly for cefepime (2.4% in 2010, 8.8% in 2022; p < 0.001), ceftazidime (5.6% in 2010, 9.4% in 2022; p = 0.014), ciprofloxacin (3.3% in 2010, 6.5% in 2022; p = 0.014), and piperacillin-tazobactam (6.4% in 2010, 11.2% in 2022; p = 0.002). No significant trends were observed for carbapenem-, aminoglycoside-, or multidrug-resistant P. aeruginosa . A high incidence was observed in patients ≥ 80 years, whereas resistance rates were high in young patients.
Conclusion
The increase in the incidence of P. aeruginosa BSIs emphasizes the importance of monitoring resistant and susceptible P. aeruginosa BSIs. Compared to the population-weighted mean resistance rates in Europe in 2022, those in Switzerland were lower, but an increase was observed for most antibiotics. The high resistance rates in young patients require further investigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Swiss Centre for Antibiotic Resistance (ANRESIS), Institute for Infectious Diseases, University of Bern, Bern, Switzerland.
- Department of Internal Medicine, Solothurner Spitäler, Spital Dornach, Dornach, Switzerland. andrea.burri@students.unibe.ch.
- Department of Emergency Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. andrea.burri@students.unibe.ch.
- Department of Emergency Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Förderung
- University of Bern
Zitieren
APA
Renggli, L., Burri, A., Ehrhard, S., Gasser, M., Kronenberg, A., & Swiss Centre for Antibiotic Resistance (2025). Incidence and resistance rates of Pseudomonas aeruginosa bloodstream infections in Switzerland: a nationwide surveillance study (2010–2022). Infection, 53(4), 1373-1381. https://doi.org/10.1007/s15010-024-02452-1
Vancouver
Renggli L, Burri A, Ehrhard S, Gasser M, Kronenberg A, Swiss Centre for Antibiotic Resistance. Incidence and resistance rates of Pseudomonas aeruginosa bloodstream infections in Switzerland: a nationwide surveillance study (2010–2022). Infection. 2025;53(4):1373-1381. doi:10.1007/s15010-024-02452-1
BibTeX
@article{Renggli2025,
author = {Renggli, Luzia and Burri, Andrea and Ehrhard, Simone and Gasser, Michael and Kronenberg, Andreas and Swiss Centre for Antibiotic Resistance, Swiss Centre for Antibiotic Resistance},
title = {Incidence and resistance rates of Pseudomonas aeruginosa bloodstream infections in Switzerland: a nationwide surveillance study (2010–2022)},
journal = {Infection},
year = {2025},
volume = {53},
number = {4},
pages = {1373--1381},
doi = {10.1007/s15010-024-02452-1}
}
EUVIMED